ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0006875

ocular hypertension

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. ocular hypertension. Diseases, record MONDO_0006875. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006875

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
ocular hypertension
Open Targets
Open Targets ID
MONDO_0006875
Open Targets
Other names
Ocular hypertension (disorder)
Open Targets
Disease Ontology
DOID:9282
Disease Ontology
MeSH
D009798
MeSH
Highest stage of its drugs
Approval, for 19 of its 48 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD
Open Targets

Drugs48

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
LATANOPROSTCHEMBL1051Small moleculeApprovalDailyMed, EMA Human Drugs and PMDA134116114Drugs and targets
TIMOLOLCHEMBL499Small moleculeApprovalDailyMed, EMA Human Drugs and PMDA1028782Drugs and targets
TRAVOPROSTCHEMBL1200799Small moleculeApprovalDailyMed, EMA Human Drugs, FDA and PMDA928178Drugs and targets
BIMATOPROSTCHEMBL1200963Small moleculeApprovalDailyMed, EMA Human Drugs and PMDA867978Drugs and targets
TIMOLOL MALEATECHEMBL1200870Small moleculeApprovalDailyMed and PMDA694540Drugs and targets
BRINZOLAMIDECHEMBL220491Small moleculeApprovalDailyMed, EMA Human Drugs and PMDA443737Drugs and targets
BRIMONIDINECHEMBL844Small moleculeApprovalTTD252421Drugs and targets
BRIMONIDINE TARTRATECHEMBL1200389Small moleculeApprovalDailyMed, EMA Human Drugs and PMDA412321Drugs and targets
TAFLUPROSTCHEMBL1963683Small moleculeApprovalDailyMed and PMDA242120Drugs and targets
NETARSUDILCHEMBL4594250Small moleculeApprovalEMA Human Drugs181616Drugs and targets

1 to 10 of 48

See all 48 drugs

Targets32

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
ADRB1Adrenergic receptor beta7Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonistApprovalhttps://conductscience.org/library/genes/153Drugs and targets
PTGFRProstaglandin F2-alpha receptor7Prostanoid FP receptor agonistApprovalhttps://conductscience.org/library/genes/5737Drugs and targets
ADRB2Adrenergic receptor beta6Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist; Beta-2 adrenergic receptor mRNA RNAi inhibitorApprovalhttps://conductscience.org/library/genes/154Drugs and targets
ROCK1Rho-associated protein kinase6Rho-associated protein kinase inhibitorApprovalhttps://conductscience.org/library/genes/6093Drugs and targets
ROCK2Rho-associated protein kinase6Rho-associated protein kinase inhibitorApprovalhttps://conductscience.org/library/genes/9475Drugs and targets
CA2Carbonic anhydrase 24Carbonic anhydrase II inhibitorApprovalhttps://conductscience.org/library/genes/760Drugs and targets
ADRA2AAdrenergic receptor alpha3Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/150Drugs and targets
ADRA2BAdrenergic receptor alpha3Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/151Drugs and targets
ADRA2CAdrenergic receptor alpha3Adrenergic receptor alpha antagonist; Adrenergic receptor alpha-2 agonistApprovalhttps://conductscience.org/library/genes/152Drugs and targets
PTGER2Prostaglandin E2 receptor EP2 subtype3Prostanoid EP2 receptor agonistApprovalhttps://conductscience.org/library/genes/5732Drugs and targets

1 to 10 of 32

See all 32 targets

Trials384

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT01632423A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)10,3372012-09-21Glaucoma, Open-Angle, Ocular HypertensionBIMATOPROSTIts record names the diseaseClinicalTrials.gov
NCT01646151A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension2,5802014-06-13Glaucoma, Open-Angle, Ocular HypertensionBIMATOPROSTIts record names the diseaseClinicalTrials.gov
NCT01853085A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons1,8302015-05-28Glaucoma, Primary Open Angle, Ocular HypertensionBIMATOPROSTIts record names the diseaseClinicalTrials.gov
NCT01999348A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting1,5532015-12-09Glaucoma, Primary Open Angle, Ocular HypertensionBIMATOPROST, TIMOLOLIts record names the diseaseClinicalTrials.gov
NCT00950690Efficacy and Tolerability of Xalatan in Patients1,2892009-08-03Glaucoma, Ocular HypertensionLATANOPROSTIts record names the diseaseClinicalTrials.gov
NCT01309204Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular HypertensionPhase 31,1842014-04-07Open-Angle Glaucoma, Ocular HypertensionBRIMONIDINE, BRINZOLAMIDEIts record names the diseaseClinicalTrials.gov
NCT01833741A Study of LUMIGAN® RC in the Clinical SettingPhase 41,1372013-09-26Glaucoma, Primary Open Angle, Ocular HypertensionBIMATOPROSTIts record names the diseaseClinicalTrials.gov
NCT01453855Travoprost 3-Month Safety and Efficacy StudyPhase 31,0992013-10-18Open-Angle Glaucoma, Ocular HypertensionTRAVOPROSTIts record names the diseaseClinicalTrials.gov
NCT01297920Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%Phase 31,0622013-07-04Open-Angle Glaucoma, Ocular HypertensionBRIMONIDINE TARTRATE, BRINZOLAMIDEIts record names the diseaseClinicalTrials.gov
NCT01297517Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%Phase 31,0012013-05-13Open-Angle Glaucoma, Ocular HypertensionBRIMONIDINE, BRIMONIDINE TARTRATE, BRINZOLAMIDEIts record names the diseaseClinicalTrials.gov

1 to 10 of 384

See all 384 trials

Comparisons in its trials120

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Generic Brinzolamide 1% Ophthalmic Suspension vs Azopt® 1% Ophthalmic Suspension: serious adverse events0 of 4890 of 475964NCT02512042Trial comparisons
Brinz/Brim vs Brinz+Brim: serious adverse events11 of 4528 of 436888NCT01309204Trial comparisons
Travoprost 0.003% vs TRAVATAN: serious adverse events5 of 4427 of 421863NCT01453855Trial comparisons
Bimatoprost 0.03% Eye Drops vs Latanoprost 0.005% Eye Drops: serious adverse events4 of 26911 of 586855NCT00541242Trial comparisons
Bimatoprost 0.01% Ophthalmic Solution vs Bimatoprost 0.03% Ophthalmic Solution: serious adverse events45 of 40040 of 398798NCT01298700Trial comparisons
Travoprost vs Latanoprost: serious adverse events5 of 3637 of 363726NCT00690794Trial comparisons
Travoprost vs Latanoprost: serious adverse events4 of 3536 of 348701NCT00761319Trial comparisons
PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: deaths from any cause0 of 3370 of 341678NCT03450629Trial comparisons
PDP-716 vs Brimonidine Tartrate Ophthalmic Solution: serious adverse events1 of 3373 of 341678NCT03450629Trial comparisons
Tafluprost vs Timolol Maleate: serious adverse events2 of 3207 of 323643NCT01026831Trial comparisons

1 to 10 of 120

See all 120 comparisons in its trials

Papers from its trials128

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
29194198RESULT2PubMed
27457469RESULT1PubMed
27457257RESULT1PubMed
27292765RESULT1PubMed
27210275RESULT1PubMed
26875002RESULT1PubMed
26563323RESULT1PubMed
25533656RESULT1PubMed
25488946RESULT1PubMed
25383466RESULT1PubMed

1 to 10 of 128

See all 128 papers from its trials

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006875

GET https://conductscience.org/api/diseases/v1/MONDO_0006875/drugs?page=2

API referenceFor AI assistants